MEC Plus – MyMedflix Member Portal

Skip to content

Live Events
Sign Up / Login

Live Events
Sign Up / Login

MEC Plus

Speciality

Author / Speaker

Title

Type of Media

Events

Search Everything

«
1
…
3
4
5
6
7
…
96
»

T-Cell NHL- Novel therapies

T-Cell NHL- Novel therapies

Steve Horwitz, MD

Myelodysplasia

Namrata S. Chandhok, MD

Acute Myeloid Leukemia

Acute Myeloid Leukemia

Talha Badar, MBBS, MD

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Javier Pinilla-Ibarz, MD, PhD

$Updates in relapsed/refractory Multiple Myeloma$

Updates in relapsed/refractory Multiple Myeloma

Sagar Lonial, MD, FACP

Advances in Multiple Myeloma in Front Line Setting

Advances in Multiple Myeloma in Front Line Setting

Ivan M. Borrello, MD

Updates on SCLC and Mesothelioma

Updates on SCLC and Mesothelioma

Triparna Sen, PhD

ADC in NSCLC: Too Much Hope?

ADC in NSCLC: Too Much Hope?

Noman Ashraf, MD

Updated Management on Advanced NSCLC Driver Mutant Tumors

Updated Management on Advanced NSCLC Driver Mutant Tumors

Edgardo S. Santos, MD, FACP, FASCO

Stage III Unresectable NSCLC: Any Progress Beyond PACIFIC?

Stage III Unresectable NSCLC: Any Progress Beyond PACIFIC?

Jorge E. Gomez, MD

Utilization of Immunotherapy in the Perioperative Setting

Utilization of Immunotherapy in the Perioperative Setting

Luis E. Raez, MD, FACP, FASCO

Understanding Germline Testing: When? Who? And What is Next?

Understanding Germline Testing: When? Who? And What is Next?

Banu Arun, MD, FASCO

Moving ctDNA Utilization Beyond Predictive Biomarkers: The Next Frontier

Moving ctDNA Utilization Beyond Predictive Biomarkers: The Next Frontier

Christian Rolfo, MD, PhD, MBA, Dr.hc

Advances in Castration-Resistant Prostate Cancer

Advances in Castration-Resistant Prostate Cancer

Mayer Fishman, MD, PhD

Updates in the Management of Kidney and Bladder Cancer

Updates in the Management of Kidney and Bladder Cancer

Pedro Barata, MD, MSc, FACP|

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Virginia Borges, MD, MMSc

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

Mark Pegram, MD

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Mariana Chavez MacGregor, MD, MSc, FASCO

Esophageal and Gastric Cancer: Moving to a More Personalized Approach

Esophageal and Gastric Cancer: Moving to a More Personalized Approach

Ahmed Zakari, MD

After ESMO 2024: What Novel Therapies Are in Use and on Development for Pancreas and Biliary Cancers?

After ESMO 2024: What Novel Therapies Are in Use and on Development for Pancreas and Biliary Cancers?

Caio Max Rocha-Lima, MD, MS

Novel Advances in Colon and Rectal Carcinomas

Novel Advances in Colon and Rectal Carcinomas

Axel Grothey, MD

Integration of Palliative Care in Oncology

Integration of Palliative Care in Oncology

Roberto Ochoa, MD

Integrative Approaches to Improve Sleep During Cancer Treatment and Survivorship

Integrative Approaches to Improve Sleep During Cancer Treatment and Survivorship

Ashwin Mehta, MD, MPH

Lifestyle Modifications in Reducing Risk of Recurrence

Lifestyle Modifications in Reducing Risk of Recurrence

Tracy E. Crane, PhD, RDN

Thyroid and Thymic Carcinomas: Where Are We Know?

Thyroid and Thymic Carcinomas: Where Are We Know?

Martin Dietrich, MD, PhD

Novel Advances for Osteosarcomas in 2025

Novel Advances for Osteosarcomas in 2025

Gina D’Amato, MD

State-of-the-Art Management in Early and Metastatic Melanoma 2025

State-of-the-Art Management in Early and Metastatic Melanoma 2025

Lilit Karapetyan, MD, MS, FACP

Antibody Drug Conjugates for HER2 Negative Breast Cancer: Advancing Breast Cancer Management

Antibody Drug Conjugates for HER2 Negative Breast Cancer: Advancing Breast Cancer Management

Suchita Pakkala, MD

Colorectal Cancer Genomic Profiling, Tumor-Informed or Tumor Naïve. Primetime and Utility?

Colorectal Cancer Genomic Profiling, Tumor-Informed or Tumor Naïve. Primetime and Utility?

Ahmed Zakari, MD

Esophageal and Gastric Carcinomas: Moving the Bar Up after ESMO 2024

Esophageal and Gastric Carcinomas: Moving the Bar Up after ESMO 2024

Mike Cusnir, MD

Displaying 121 - 150 of 2,875

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Useful Links

Library
Live Events

Categories

MEC Basic
MEC Plus
Purchased

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok